2006
DOI: 10.1021/cr050263h
|View full text |Cite
|
Sign up to set email alerts
|

Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents:  Potential Therapeutics for Neurological and Psychiatric Disorders

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
151
0

Year Published

2007
2007
2020
2020

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 358 publications
(151 citation statements)
references
References 232 publications
0
151
0
Order By: Relevance
“…Sensitive detection of neurotransmitters is the cornerstone for advancing the understanding of neurological processes. 2 Dopamine and serotonin, which regulate numerous biological processes, are the most humanly important neurotransmitters. 3 Dopamine deficiency causes major clinical symptoms of Parkinson's disease (PD).…”
Section: * S Supporting Informationmentioning
confidence: 99%
“…Sensitive detection of neurotransmitters is the cornerstone for advancing the understanding of neurological processes. 2 Dopamine and serotonin, which regulate numerous biological processes, are the most humanly important neurotransmitters. 3 Dopamine deficiency causes major clinical symptoms of Parkinson's disease (PD).…”
Section: * S Supporting Informationmentioning
confidence: 99%
“…[9][10][11] SB269652 (1) 12,13 was recently described as the first small molecule negative allosteric modulator of the D 2 R. 13 This was somewhat surprising, given that 1 contains structural features of numerous orthosteric D 2 -like receptor ligands. 12,[14][15][16] Indeed, the 1,2,3,4-tetrahydroisoquinoline (THIQ) 'head' group of 1 contains a basic tertiary amine that is expected to form a salt bridge with the conserved aspartate (Asp 3.32 , Ballosteros-Weinstein nomenclature 17 ) of aminergic GPCRs, and would thus compete with the binding of dopamine.…”
Section: Introductionmentioning
confidence: 99%
“…10 Here, we report the synthesis and biological evaluation of (4-arylpiperazinyl)-piperidines as BACE 1 inhibitors.…”
mentioning
confidence: 99%